# The Inducible Costimulator (ICOS) Is Critical for the De <sub>H</sub> 17 Cells

Science Translational Medicine

2, 55ra78

DOI: 10.1126/scitranslmed.3000448

Citation Report

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | ICOStomizing Immunotherapies with T <sub>H</sub> 17. Science Translational Medicine, 2010, 2, 55ps52. | 5.8 | 6 |
| 2 | Regulation of interleukin-10 and interleukin-22 expression in T helper cells. Current Opinion in Immunology, 2011, 23, 605-612. | 2.4 | 64 |
| 3 | T Helper Cell Differentiation. Advances in Immunology, 2011, 109, 159-196. | 1.1 | 89 |
| 4 | Protective Effector Memory CD4 T Cells Depend on ICOS for Survival. PLoS ONE, 2011, 6, e16529. | 1.1 | 21 |
| 5 | Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOS. Blood, 2011, 118, 3062-3071. | 0.6 | 32 |
| 6 | CD5 costimulation induces stable Th17 development by promoting IL-23R expression and sustained STAT3 activation. Blood, 2011, 118, 6107-6114. | 0.6 | 43 |
| 7 | Quantitative events determine the differentiation and function of helper T cells. Nature Immunology, 2011, 12, 288-294. | 7.0 | 58 |
| 8 | Critical co-stimulatory pathways in the stability of Foxp3+ Treg cell homeostasis in Type I Diabetes. Autoimmunity Reviews, 2011, 11, 104-111. | 2.5 | 20 |
| 9 | Inducible Costimulator Controls Migration of T Cells to the Lungs via Down-Regulation of CCR7 and CD62L. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 843-850. | 1.4 | 16 |
| 10 | Human T <sub>H</sub> 17 Cells Are Long-Lived Effector Memory Cells. Science Translational Medicine, 2011, 3, 104ra100. | 5.8 | 236 |
| 11 | Significance of T helper 17 immunity in transplantation. Current Opinion in Organ Transplantation, 2012, 17, 8-14. | 0.8 | 49 |
| 12 | Bcl6 and Maf Cooperate To Instruct Human Follicular Helper CD4 T Cell Differentiation. Journal of Immunology, 2012, 188, 3734-3744. | 0.4 | 302 |
| 13 | A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth. OncoImmunology, 2012, 1, 172-178. | 2.1 | 42 |
| 14 | ICOS-LICOS interaction is critically involved in TGN1412-mediated T-cell activation. Blood, 2012, 119, 6268-6277. | 0.6 | 21 |
| 15 | Functional niche of inflamed synovium for Th17-cell expansion and activation in rheumatoid arthritis: Implication to clinical therapeutics. Autoimmunity Reviews, 2012, 11, 844-851. | 2.5 | 31 |
| 16 | Defining the human T helper 17 cell phenotype. Trends in Immunology, 2012, 33, 505-512. | 2.9 | 162 |
| 17 | Regulation of TH17 cell differentiation by innate immune signals. Cellular and Molecular Immunology, 2012, 9, 287-295. | 4.8 | 89 |
| 18 | Biomimetic Delivery with Microâ€•and Nanoparticles. Advanced Materials, 2012, 24, 3757-3778. | 11.1 | 145 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Type17 T-cells in Central Nervous System Autoimmunity and Tumors. Journal of Clinical Immunology, 2012, 32, 802-808. | 2.0 | 26 |
| 20 | The Role of Costimulatory Molecules in Directing the Functional Differentiation of Alloreactive T Helper Cells. American Journal of Transplantation, 2012, 12, 2588-2600. | 2.6 | 45 |
| 21 | Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology. Immunity, 2013, 39, 49-60. | 6.6 | 418 |
| 22 | Modulation of p38 MAPK signaling enhances dendritic cell activation of human CD4+ Th17 responses to ovarian tumor antigen. Cancer Immunology, Immunotherapy, 2013, 62, 839-849. | 2.0 | 24 |
| 23 | Th17 Cells in Autoimmune Inflammation and Demyelination in the Central Nervous System. , 2013, , 1-25. | | 1 |
| 24 | Bispecific T-cells Expressing Polyclonal Repertoire of Endogenous Î³Î´ T-cell Receptors and Introduced CD19-specific Chimeric Antigen Receptor. Molecular Therapy, 2013, 21, 638-647. | 3.7 | 134 |
| 25 | Essentials of Th17 cell commitment and plasticity. Blood, 2013, 121, 2402-2414. | 0.6 | 306 |
| 26 | Immune Co-signaling to Treat Cancer. , 2013, , 211-280. | | 1 |
| 27 | B7h (ICOS-L) Maintains Tolerance at the Fetomaternal Interface. American Journal of Pathology, 2013, 182, 2204-2213. | 1.9 | 30 |
| 28 | Human Inflammatory Dendritic Cells Induce Th17 Cell Differentiation. Immunity, 2013, 38, 336-348. | 6.6 | 556 |
| 29 | Adipocytes as immune regulatory cells. International Immunopharmacology, 2013, 16, 224-231. | 1.7 | 40 |
| 30 | <scp>IL</scp>â€22, not simply a Th17 cytokine. Immunological Reviews, 2013, 252, 116-132. | 2.8 | 391 |
| 31 | IL-21â€“Producing Th Cells in Immunity and Autoimmunity. Journal of Immunology, 2013, 191, 3501-3506. | 0.4 | 100 |
| 32 | â€œModel Tâ€•Cells: A Time-Tested Vehicle for Gene Therapy. Frontiers in Immunology, 2013, 4, 304. | 2.2 | 8 |
| 33 | CagA-Dependent Downregulation of B7-H2 Expression on Gastric Mucosa and Inhibition of Th17 Responses during Helicobacter pylori Infection. Journal of Immunology, 2013, 191, 3838-3846. | 0.4 | 48 |
| 34 | Triggering of B7h by the ICOS Modulates Maturation and Migration of Monocyte-Derived Dendritic Cells. Journal of Immunology, 2013, 190, 1125-1134. | 0.4 | 28 |
| 35 | Enhanced Function of Redirected Human T Cells Expressing Linker for Activation of T Cells That Is Resistant to Ubiquitylation. Human Gene Therapy, 2013, 24, 27-37. | 1.4 | 18 |
| 36 | Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression. PLoS ONE, 2013, 8, e57820. | 1.1 | 213 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Attenuation of Immune-Mediated Influenza Pneumonia by Targeting the Inducible Co-Stimulator (ICOS) Molecule on T Cells. PLoS ONE, 2014, 9, e100970. | 1.1 | 11 |
| 38 | ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood, 2014, 124, 1070-1080. | 0.6 | 268 |
| 39 | Exploiting the curative potential of adoptive Tâ€cell therapy for cancer. Immunological Reviews, 2014, 257, 56-71. | 2.8 | 422 |
| 40 | Monocyte-derived dendritic cells from Crohn's disease patients exhibit decreased ability to activate T helper type 17 responses in memory cells. Clinical and Experimental Immunology, 2014, 177, 190-202. | 1.1 | 4 |
| 41 | The Immunological Synapse. Cancer Immunology Research, 2014, 2, 1023-1033. | 1.6 | 330 |
| 42 | High CTLA-4 Expression on Th17 Cells Results in Increased Sensitivity to CTLA-4 Coinhibition and Resistance to Belatacept. American Journal of Transplantation, 2014, 14, 607-614. | 2.6 | 50 |
| 43 | Ovarian Tumor Ascites CD14+ Cells Suppress Dendritic Cellâ€“activated CD4+ T-cell Responses Through IL-10 Secretion and Indoleamine 2,3-Dioxygenase. Journal of Immunotherapy, 2014, 37, 163-169. | 1.2 | 21 |
| 44 | Th17 Cells in Cancer: The Ultimate Identity Crisis. Frontiers in Immunology, 2014, 5, 276. | 2.2 | 257 |
| 45 | Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. Cytotherapy, 2014, 16, 619-630. | 0.3 | 90 |
| 46 | An easy way to make a good anti-tumor chimeric antigen receptor TÂcell?. Cytotherapy, 2014, 16, 577-578. | 0.3 | 0 |
| 47 | B7h Triggering Inhibits the Migration of Tumor Cell Lines. Journal of Immunology, 2014, 192, 4921-4931. | 0.4 | 40 |
| 48 | Chimeric Antigen Receptor Therapy for Cancer. Annual Review of Medicine, 2014, 65, 333-347. | 5.0 | 319 |
| 49 | Targeting co-stimulatory pathways: transplantation and autoimmunity. Nature Reviews Nephrology, 2014, 10, 14-24. | 4.1 | 137 |
| 50 | Candida-Elicited Murine Th17 Cells Express High CTLA-4 Compared with Th1 Cells and Are Resistant to Costimulation Blockade. Journal of Immunology, 2014, 192, 2495-2504. | 0.4 | 28 |
| 51 | Phenotype and functions of memory Tfh cells in human blood. Trends in Immunology, 2014, 35, 436-442. | 2.9 | 365 |
| 52 | Adoptive immunotherapy for cancer. Immunological Reviews, 2014, 257, 14-38. | 2.8 | 119 |
| 53 | Activating and Propagating Polyclonal Gamma Delta T Cells with Broad Specificity for Malignancies. Clinical Cancer Research, 2014, 20, 5708-5719. | 3.2 | 114 |
| 54 | Increased Production of Interleukinâ€17 Over Interleukinâ€10 by Treg Cells Implicates Inducible Costimulator Molecule in Experimental Spondyloarthritis. Arthritis and Rheumatology, 2014, 66, 2412-2422. | 2.9 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. Journal of Experimental Medicine, 2014, 211, 715-725. | 4.2 | 242 |
| 56 | Association of Inducible T Cell Costimulator Polymorphisms with Susceptibility and Outcome of Hepatitis B Virus Infection in a Chinese Han Population. Scandinavian Journal of Immunology, 2015, 82, 275-281. | 1.3 | 6 |
| 57 | Inducible Costimulator Gene-Transduced Bone Marrow-Derived Mesenchymal Stem Cells Attenuate the Severity of Acute Graft-Versus-Host Disease in Mouse Models. Cell Transplantation, 2015, 24, 1717-1731. | 1.2 | 12 |
| 58 | Chimeric Antigen Receptor T-Cells. Cancer Journal (Sudbury, Mass ), 2015, 21, 475-479. | 1.0 | 11 |
| 59 | Harnessing the Therapeutic Potential of Th17 Cells. Mediators of Inflammation, 2015, 2015, 1-11. | 1.4 | 32 |
| 60 | The Inducible Costimulator Augments Tc17 Cell Responses to Self and Tumor Tissue. Journal of Immunology, 2015, 194, 1737-1747. | 0.4 | 34 |
| 61 | Antibody-Opsonized Bacteria Evoke an Inflammatory Dendritic Cell Phenotype and Polyfunctional Th Cells by Cross-Talk between TLRs and FcRs. Journal of Immunology, 2015, 194, 1856-1866. | 0.4 | 33 |
| 62 | Interleukin-22: Immunobiology and Pathology. Annual Review of Immunology, 2015, 33, 747-785. | 9.5 | 679 |
| 63 | Monogenic mutations differentially affect the quantity and quality of T follicular helper cells in patients with human primary immunodeficiencies. Journal of Allergy and Clinical Immunology, 2015, 136, 993-1006.e1. | 1.5 | 181 |
| 64 | Chimeric Antigen Receptorâ€“ and TCR-Modified T Cells Enter Main Street and Wall Street. Journal of Immunology, 2015, 195, 755-761. | 0.4 | 147 |
| 65 | The pharmacology of second-generation chimeric antigen receptors. Nature Reviews Drug Discovery, 2015, 14, 499-509. | 21.5 | 411 |
| 66 | Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling. Clinical Cancer Research, 2015, 21, 2546-2557. | 3.2 | 25 |
| 67 | New insights into T-cell cosignaling in allograft rejection and survival. Current Opinion in Organ Transplantation, 2015, 20, 43-48. | 0.8 | 8 |
| 68 | Astute Clinician Report: A Novel 10Âbp Frameshift Deletion in Exon 2 of ICOS Causes a Combined Immunodeficiency Associated with an Enteritis and Hepatitis. Journal of Clinical Immunology, 2015, 35, 598-603. | 2.0 | 30 |
| 69 | Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. Seminars in Oncology, 2015, 42, 640-655. | 0.8 | 179 |
| 70 | Novel immunotherapies for hematologic malignancies. Immunological Reviews, 2015, 263, 90-105. | 2.8 | 44 |
| 71 | Going viral: chimeric antigen receptor Tâ€cell therapy for hematological malignancies. Immunological Reviews, 2015, 263, 68-89. | 2.8 | 290 |
| 72 | CAR T Cell Therapy: A Game Changer in Cancer Treatment. Journal of Immunology Research, 2016, 2016, 1-10. | 0.9 | 122 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Interleukin-22 Signaling in the Regulation of Intestinal Health and Disease. Frontiers in Cell and Developmental Biology, 2015, 3, 85. | 1.8 | 145 |
| 74 | Interaction among activated lymphocytes and mesenchymal cells through podoplanin is critical for a high IL-17 secretion. Arthritis Research and Therapy, 2016, 18, 148. | 1.6 | 45 |
| 75 | Analysis of CXCR5+Th17 cells in relation to disease activity and TNF inhibitor therapy in Rheumatoid Arthritis. Scientific Reports, 2016, 6, 39474. | 1.6 | 17 |
| 76 | Chimeric antigen receptor-modified T cells strike back. International Immunology, 2016, 28, 355-363. | 1.8 | 20 |
| 77 | Inducible costimulator (ICOS) potentiates TCR-induced calcium flux by augmenting PLCÎ³1 activation and actin remodeling. Molecular Immunology, 2016, 79, 38-46. | 1.0 | 22 |
| 79 | Current status of chimeric antigen receptor therapy for haematological malignancies. British Journal of Haematology, 2016, 172, 11-22. | 1.2 | 70 |
| 80 | Transcriptional and functional characterization of CD137L-dendritic cells identifies a novel dendritic cell phenotype. Scientific Reports, 2016, 6, 29712. | 1.6 | 10 |
| 81 | Synthetic RORÎ³ agonists regulate multiple pathways to enhance antitumor immunity. OncoImmunology, 2016, 5, e1254854. | 2.1 | 68 |
| 82 | Inducible T-cell co-stimulator ligand (ICOSL) blockade leads to selective inhibition of anti-KLH IgG responses in subjects with systemic lupus erythematosus. Lupus Science and Medicine, 2016, 3, e000146. | 1.1 | 57 |
| 83 | Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells. Seminars in Oncology, 2016, 43, 291-299. | 0.8 | 13 |
| 84 | Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic. Cancer Immunology, Immunotherapy, 2016, 65, 247-259. | 2.0 | 35 |
| 85 | Clinical pharmacology of CAR-T cells: Linking cellular pharmacodynamics to pharmacokinetics and antitumor effects. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 90-100. | 3.3 | 22 |
| 86 | The Principles of Engineering Immune Cells to Treat Cancer. Cell, 2017, 168, 724-740. | 13.5 | 844 |
| 87 | Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nature Communications, 2017, 8, 14340. | 5.8 | 110 |
| 88 | Practical considerations for chimeric antigen receptor design and delivery. Expert Opinion on Biological Therapy, 2017, 17, 961-978. | 1.4 | 10 |
| 89 | High frequencies of circulating Tfh-Th17 cells in myasthenia gravis patients. Neurological Sciences, 2017, 38, 1599-1608. | 0.9 | 25 |
| 90 | Interleukin-22 in human inflammatory diseases and viral infections. Autoimmunity Reviews, 2017, 16, 1209-1218. | 2.5 | 67 |
| 91 | Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy. Current Hematologic Malignancy Reports, 2017, 12, 335-343. | 1.2 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 92 | Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence. Nature Communications, 2017, 8, 1961. | 5.8 | 67 |
| 93 | Antigen-specific regulatory T cells: are police CARs the answer?. Translational Research, 2017, 187, 53-58. | 2.2 | 39 |
| 94 | Gene therapy in hematopoietic cell transplants. , 0, , 649-656. | | 0 |
| 96 | CAR-T Cells: Next Generation Cancer Therapeutics. Journal of the Indian Institute of Science, 2018, 98, 21-31. | 0.9 | 0 |
| 97 | IL-23 and IL-1Î² Drive Human Th17 Cell Differentiation and Metabolic Reprogramming in Absence of CD28 Costimulation. Cell Reports, 2018, 22, 2642-2653. | 2.9 | 157 |
| 98 | Targeting Wnt/Î²-Catenin Signaling for Cancer Immunotherapy. Trends in Pharmacological Sciences, 2018, 39, 648-658. | 4.0 | 159 |
| 99 | Dysregulated T cells in multiple sclerosis. Clinical and Experimental Neuroimmunology, 2018, 9, 20-29. | 0.5 | 23 |
| 100 | Activated T follicular helper-like cells are released into blood after oral vaccination and correlate with vaccine specific mucosal B-cell memory. Scientific Reports, 2018, 8, 2729. | 1.6 | 51 |
| 101 | The Major Orphan Forms of Ichthyosis Are Characterized by Systemic T-Cell Activation and Th-17/Tc-17/Th-22/Tc-22 Polarization in Blood. Journal of Investigative Dermatology, 2018, 138, 2157-2167. | 0.3 | 43 |
| 102 | Engineering T cells for adoptive therapy: outsmarting the tumor. Current Opinion in Immunology, 2018, 51, 133-139. | 2.4 | 10 |
| 103 | When worlds collide: Th17 and Treg cells in cancer and autoimmunity. Cellular and Molecular Immunology, 2018, 15, 458-469. | 4.8 | 331 |
| 104 | Mechanistic insights into cancer immunity and immunotherapy. Cellular and Molecular Immunology, 2018, 15, 419-420. | 4.8 | 30 |
| 105 | ICOSL-augmented adenoviral-based vaccination induces a bipolar Th17/Th1 T cell response against unglycosylated MUC1 antigen. Vaccine, 2018, 36, 6262-6269. | 1.7 | 6 |
| 106 | In Vitro Priming of Adoptively Transferred T Cells with a RORÎ³ Agonist Confers Durable Memory and Stemness In Vivo. Cancer Research, 2018, 78, 3888-3898. | 0.4 | 30 |
| 107 | CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies. Frontiers in Immunology, 2018, 9, 1740. | 2.2 | 155 |
| 108 | Inducible T-Cell Co-Stimulator Impacts Chronic Graft-Versus-Host Disease by Regulating Both Pathogenic and Regulatory T Cells. Frontiers in Immunology, 2018, 9, 1461. | 2.2 | 19 |
| 109 | Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017,) Tj ETQq0 0 0 rgBT /Overlock | | 12 |
| 110 | NAD-Biosynthetic and Consuming Enzymes as Central Players of Metabolic Regulation of Innate and Adaptive Immune Responses in Cancer. Frontiers in Immunology, 2019, 10, 1720. | 2.2 | 52 |

| # | Article | IF | Citations |
|---|---|---|---|
| 111 | TLR7 and TLR8 activate distinct pathways in monocytes during RNA virus infection. Science Signaling, 2019, 12, . | 1.6 | 129 |
| 112 | Helicobacter pylori Deregulates T and B Cell Signaling to Trigger Immune Evasion. Current Topics in Microbiology and Immunology, 2019, 421, 229-265. | 0.7 | 23 |
| 113 | Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clinical and Translational Immunology, 2019, 8, e1049. | 1.7 | 205 |
| 114 | Co-stimulatory and co-inhibitory pathways in cancer immunotherapy. Advances in Cancer Research, 2019, 143, 145-194. | 1.9 | 53 |
| 115 | Dysregulation of T Follicular Helper Cells in Lupus. Journal of Immunology, 2019, 202, 1649-1658. | 0.4 | 34 |
| 116 | Lung Cancer Heterogeneity in Modulation of Th17/IL17A Responses. Frontiers in Oncology, 2019, 9, 1384. | 1.3 | 7 |
| 117 | Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 199-224. | 3.3 | 53 |
| 118 | Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases. Journal of Allergy and Clinical Immunology, 2019, 143, 2095-2107. | 1.5 | 33 |
| 119 | Emerging Cellular Therapies for Cancer. Annual Review of Immunology, 2019, 37, 145-171. | 9.5 | 263 |
| 120 | Î³Î´ T Cells Promote Steatohepatitis by Orchestrating Innate and Adaptive Immune Programming. Hepatology, 2020, 71, 477-494. | 3.6 | 41 |
| 121 | Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood. Journal of Allergy and Clinical Immunology, 2020, 145, 215-228. | 1.5 | 70 |
| 122 | Targeting the interleukin-17 immune axis for cancer immunotherapy. Journal of Experimental Medicine, 2020, 217, . | 4.2 | 105 |
| 123 | Contributions of T cells in multiple sclerosis: what do we currently know?. Journal of Neurology, 2021, 268, 4587-4593. | 1.8 | 15 |
| 124 | A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq. Molecular Therapy, 2020, 28, 2577-2592. | 3.7 | 58 |
| 125 | Immunosuppression in vascularized composite allotransplant: the search for an effective and safe treatment continues. Transplant International, 2020, 33, 1291-1293. | 0.8 | 2 |
| 126 | Role of effector TÂcells in multiple sclerosis. Clinical and Experimental Neuroimmunology, 2020, 11, 140-147. | 0.5 | 3 |
| 127 | IL6 Fuels Durable Memory for Th17 Cellâ€“Mediated Responses to Tumors. Cancer Research, 2020, 80, 3920-3932. | 0.4 | 16 |
| 128 | c-MAF, a Swiss Army Knife for Tolerance in Lymphocytes. Frontiers in Immunology, 2020, 11, 206. | 2.2 | 39 |

| # | Article | IF | Citations |
|---|---|---|---|
| 129 | CD28-Dependent CTLA-4 Expression Fine-Tunes the Activation of Human Th17 Cells. IScience, 2020, 23, 100912. | 1.9 | 5 |
| 130 | IL-10 and IL-22 in Mucosal Immunity: Driving Protection and Pathology. Frontiers in Immunology, 2020, 11, 1315. | 2.2 | 106 |
| 131 | Identification of human CD4 <sup>+</sup> T cell populations with distinct antitumor activity. Science Advances, 2020, 6, . | 4.7 | 27 |
| 132 | Regulatory T cells and T helper 17 cells in viral infection. Scandinavian Journal of Immunology, 2020, 91, e12873. | 1.3 | 48 |
| 133 | Inclusion of Dap10 or 4-1BB costimulation domains in the chPD1 receptor enhances anti-tumor efficacy of T cells in murine models of lymphoma and melanoma. Cellular Immunology, 2020, 351, 104069. | 1.4 | 15 |
| 134 | The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy. ESMO Open, 2020, 5, e000544. | 2.0 | 95 |
| 135 | Chimeric antigen receptorâ€modified Tâ€cell therapy for plateletâ€derived growth factor receptor Î±â€positive rhabdomyosarcoma. Cancer, 2020, 126, 2093-2100. | 2.0 | 13 |
| 136 | Regulation of mRNA stability by RBPs and noncoding RNAs contributing to the pathogenicity of Th17 cells. RNA Biology, 2021, 18, 647-656. | 1.5 | 9 |
| 137 | Lessons on SpA pathogenesis from animal models. Seminars in Immunopathology, 2021, 43, 207-219. | 2.8 | 15 |
| 138 | An enhanced level of LAMP-2A participates in CD4+T cell hyperactivity in patients with primary biliary cholangitis. Annals of Translational Medicine, 2021, 9, 101-101. | 0.7 | 5 |
| 139 | Effective Activation and Expansion of Canine Lymphocytes Using a Novel Nano-Sized Magnetic Beads Approach. Frontiers in Immunology, 2021, 12, 604066. | 2.2 | 8 |
| 140 | Interleukin-22 Influences the Th1/Th17 Axis. Frontiers in Immunology, 2021, 12, 618110. | 2.2 | 20 |
| 141 | Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression. Cancers, 2021, 13, 1300. | 1.7 | 10 |
| 143 | The Potential of Harnessing IL-2-Mediated Immunosuppression to Prevent Pathogenic B Cell Responses. Frontiers in Immunology, 2021, 12, 667342. | 2.2 | 6 |
| 144 | B Cell-mediated Humoral Immunity in Chronic Hepatitis B Infection. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000. | 0.7 | 6 |
| 145 | Neonatal T Helper 17 Responses Are Skewed Towards an Immunoregulatory Interleukin-22 Phenotype. Frontiers in Immunology, 2021, 12, 655027. | 2.2 | 10 |
| 147 | Follicular Helper CD4+ T Cells, Follicular Regulatory CD4+ T Cells, and Inducible Costimulator and Their Roles in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. Mediators of Inflammation, 2021, 2021, 1-10. | 1.4 | 14 |
| 148 | Interactome Networks of FOSL1 and FOSL2 in Human Th17 Cells. ACS Omega, 2021, 6, 24834-24847. | 1.6 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 149 | Poor CD4+ T Cell Immunogenicity Limits Humoral Immunity to P.Âfalciparum Transmission-Blocking Candidate Pfs25 in Humans. Frontiers in Immunology, 2021, 12, 732667. | 2.2 | 6 |
| 150 | Approaches of T Cell Activation and Differentiation for CAR-T Cell Therapies. Methods in Molecular Biology, 2020, 2086, 203-211. | 0.4 | 7 |
| 151 | Interleukin-10 Family Cytokines Immunobiology and Structure. Advances in Experimental Medicine and Biology, 2019, 1172, 79-96. | 0.8 | 60 |
| 152 | Role of Co-stimulatory Molecules in T Helper Cell Differentiation. Advances in Experimental Medicine and Biology, 2019, 1189, 153-177. | 0.8 | 19 |
| 153 | STING agonist promotes CAR T cell trafficking and persistence in breast cancer. Journal of Experimental Medicine, 2021, 218, . | 4.2 | 84 |
| 154 | Anti-ICOS mAb Targets Pathogenic IL-17A-expressing Cells in Canine Model of Chronic GVHD. Transplantation, 2021, 105, 1008-1016. | 0.5 | 2 |
| 155 | Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease. JCI Insight, 2016, 1, . | 2.3 | 37 |
| 156 | Î²-catenin and PI3KÎ´ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity. JCI Insight, 2017, 2, . | 2.3 | 35 |
| 157 | Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion. JCI Insight, 2017, 2, e90772. | 2.3 | 54 |
| 158 | An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. JCI Insight, 2017, 2, . | 2.3 | 53 |
| 159 | TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis. Journal of Clinical Investigation, 2020, 130, 1863-1878. | 3.9 | 51 |
| 160 | Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability. Journal of Clinical Investigation, 2020, 130, 3087-3097. | 3.9 | 110 |
| 161 | The NF-Î°B regulator MALT1 determines the encephalitogenic potential of Th17 cells. Journal of Clinical Investigation, 2012, 122, 4698-4709. | 3.9 | 106 |
| 162 | Polyfunctional T-Cell Responses Are Disrupted by the Ovarian Cancer Ascites Environment and Only Partially Restored by Clinically Relevant Cytokines. PLoS ONE, 2010, 5, e15625. | 1.1 | 27 |
| 163 | Anti-Chlamydial Th17 Responses Are Controlled by the Inducible Costimulator Partially through Phosphoinositide 3-Kinase Signaling. PLoS ONE, 2012, 7, e52657. | 1.1 | 28 |
| 164 | IL-17 Enhances Chemotaxis of Primary Human B Cells during Asthma. PLoS ONE, 2014, 9, e114604. | 1.1 | 20 |
| 165 | Development of interleukin-17-producing VÎ³2+ Î³Î´ T cells is reduced by ICOS signaling in the thymus. Oncotarget, 2016, 7, 19341-19354. | 0.8 | 24 |
| 166 | Modulating Co-Stimulation During Antigen Presentation to Enhance Cancer Immunotherapy. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2012, 12, 224-235. | 0.5 | 45 |

| # | Article | IF | Citations |
|---|---|---|---|
| 167 | Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy. Cells, 2021, 10, 14. | 1.8 | 34 |
| 168 | Immune evasion strategies used byHelicobacter pylori. World Journal of Gastroenterology, 2014, 20, 12753. | 1.4 | 92 |
| 169 | The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors. Chinese Journal of Cancer, 2014, 33, 421-433. | 4.9 | 9 |
| 171 | T-bet: A Critical Regulator of Encephalitogenic T Cells. , 2013, , 49-70. | | 0 |
| 172 | Interleukin-22: A Bridge Between Epithelial Innate Host Defense and Immune Cells. , 2014, , 147-177. | | 0 |
| 173 | Th17 Cells in Cancer. , 2014, , 37-75. | | 0 |
| 174 | Quality of CTL Therapies: A Changing Landscape. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 303-349. | 0.1 | 0 |
| 175 | Immunopharmacologic Approaches to Treat Cancer. , 2016, , 397-425. | | 0 |
| 176 | Role of Th17 cell in tissue inflammation and organ-specific autoimmunity. , 2022, , 93-121. | | 2 |
| 179 | T Helper Cells Fate Mapping by Co-stimulatory Molecules and its Functions in Allograft Rejection and Tolerance. International Journal of Organ Transplantation Medicine, 2014, 5, 97-110. | 0.5 | 16 |
| 180 | The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer Immunotherapies. Journal of Immunology Research and Therapy, 2017, 2, 68-79. | 1.0 | 20 |
| 181 | Antitumor effects and persistence of a novel HER2 CAR T cells directed to gastric cancer in preclinical models. American Journal of Cancer Research, 2018, 8, 106-119. | 1.4 | 18 |
| 183 | Association between polymorphisms and risk of colorectal cancer: a case-control study involving 2,606 subjects. International Journal of Clinical and Experimental Pathology, 2018, 11, 2822-2830. | 0.5 | 0 |
| 184 | Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies. Pharmacological Research, 2022, 175, 106036. | 3.1 | 31 |
| 185 | B cells imprint adoptively transferred CD8<sup>+</sup>T cells with enhanced tumor immunity. , 2022, 10, e003078. | | 7 |
| 186 | Remodeling metabolic fitness: Strategies for improving the efficacy of chimeric antigen receptor T cell therapy. Cancer Letters, 2022, 529, 139-152. | 3.2 | 18 |
| 187 | ICOS Gene Polymorphisms (IVS1 + 173 T/C and c. 1624 C/T) in Primary SjÃ¶grenâ€™s Syndrome Patients: Analysis of ICOS Expression. Current Issues in Molecular Biology, 2022, 44, 764-776. | 1.0 | 3 |
| 188 | A Pathogenic Th17/CD38+ Macrophage Feedback Loop Drives Inflammatory Arthritis through TNF-Î±. Journal of Immunology, 2022, 208, 1315-1328. | 0.4 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 189 | STAT3 Role in T-Cell Memory Formation. International Journal of Molecular Sciences, 2022, 23, 2878. | 1.8 | 10 |
| 190 | Interleukin-22 in Renal Protection and Its Pathological Role in Kidney Diseases. Frontiers in Immunology, 2022, 13, 851818. | 2.2 | 3 |
| 192 | Trafficking and persistence of alloantigen-specific chimeric antigen receptor regulatory TÂcells in Cynomolgus macaque. Cell Reports Medicine, 2022, 3, 100614. | 3.3 | 7 |
| 194 | The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook. Frontiers in Immunology, 0, 13, . | 2.2 | 2 |
| 195 | Parallel CD19/CD20 CAR-Activated T-Cells Are More Effective for Refractory B-Cell Lymphoma In Vitro and In Vivo. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-10. | 0.5 | 3 |
| 196 | CAR-T cell potency: from structural elements to vector backbone components. Biomarker Research, 2022, 10, . | 2.8 | 14 |
| 197 | Immuno-PET Monitoring of CD8+ T Cell Infiltration Post ICOS Agonist Antibody Treatment Alone and in Combination with PD-1 Blocking Antibody Using a 89Zr Anti-CD8+ Mouse Minibody in EMT6 Syngeneic Tumor Mouse. Molecular Imaging and Biology, 2023, 25, 528-540. | 1.3 | 1 |
| 198 | Metabolic requirements of Th17 cells and of B cells: Regulation and defects in health and in inflammatory diseases. Frontiers in Immunology, 0, 13, . | 2.2 | 5 |
| 200 | Targeting CAR T Cellsâ€™ Metabolic Pathways to Boost Their Effectiveness Against Tumors. , 2023, , 1-19. | | 0 |
| 201 | The role of Th17 cells in chronic lymphocytic leukemia: friend orÂfoe?. Blood Advances, 2023, 7, 2401-2417. | 2.5 | 1 |
| 202 | Interleukin 27 is a novel cytokine with anti-inflammatory effects against spondyloarthritis through the suppression of Th17 responses. Frontiers in Immunology, 0, 13, . | 2.2 | 1 |
| 203 | Targeting Cbl-b in cancer immunotherapy. , 2023, 11, e006007. | | 14 |
| 204 | <scp>Nonâ€Redundant</scp> Roles of T Cell Costimulation Pathways in Inflammatory Arthritis Revealed by Dual Blockade of <scp>ICOS</scp> and <scp>CD28</scp> with Acazicolcept (<scp>ALPN</scp>â€101). Arthritis and Rheumatology, 2023, 75, 1344-1356. | 2.9 | 3 |
| 205 | Role and Potential of Different T Helper Cell Subsets in Adoptive Cell Therapy. Cancers, 2023, 15, 1650. | 1.7 | 2 |
| 206 | Targeting of chimeric antigen receptor T cell metabolism to improve therapeutic outcomes. Frontiers in Immunology, 0, 14, . | 2.2 | 4 |
| 207 | Systemic Administration of Acazicolcept, a Dual CD28 and Inducible T cell Costimulator Inhibitor, Ameliorates Experimental Autoimmune Uveitis. Translational Vision Science and Technology, 2023, 12, 27. | 1.1 | 0 |
| 208 | Immune checkpoints on T and NK cells in the context of HBV infection: Landscape, pathophysiology and therapeutic exploitation. Frontiers in Immunology, 0, 14, . | 2.2 | 2 |
| 209 | Augmenting TCR signal strength and ICOS costimulation results in metabolically fit and therapeutically potent human CAR Th17 cells. Molecular Therapy, 2023, 31, 2120-2131. | 3.7 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|